Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Next Previous
X
Search
Trial Profile

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BL M11D1 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors SystImmune

    • Most Recent Events

    • 26 Nov 2024 According to a SystImmune media release, the company will present Initial results from First-in-Human Phase 1 Study at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being hosted Monday, December 9th, 2024, 6:00 PM-8:00 PM PST in San Diego, CA.
    • 15 Oct 2024 New trial record
    • 14 Oct 2024 According to a SystImmune media release, the company announced that they are excited to receive the FDA Study-May-Proceed letter enabling the initiation of Phase 1 study with BL-M11D1.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top